Skip Navigation

European Journal of Heart Failure 2005 7(4):618-623; doi:10.1016/j.ejheart.2004.04.015
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Al-Hesayen, A.
Right arrow Articles by Parker, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Hesayen, A.
Right arrow Articles by Parker, J. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

Selective versus nonselective β-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization

Abdul Al-Hesayena, Eduardo R. Azevedoa, John S. Florasa, Shauna Hollingsheadb, Gary D. Lopaschukb and John D. Parkera,*

a Division of Cardiology, Department of Medicine, Mount Sinai Hospital and University Health Network Hospitals, University of Toronto 600 University Avenue, Suite 1609, Toronto, Ontario, Canada, M5G 1X5
b The Department of Pediatrics, Faculty of Medicine and Dentistry, University Hospital, University of Alberta Edmonton, Canada

* Corresponding author. Tel.: +1-416-586-4794; Fax: +1-416-586-8413. E-mail address: jdp{at}ca.inter.net


   Abstract

Background: Non-selective and selective β-blockers have been shown to improve outcomes in chronic heart failure (CHF). Recent data suggests the non-selective β-blockers have a more favourable effect on outcomes than β1-selective agents. We sought to examine the differential effects of non-selective versus selective β-blockade on myocardial substrate utilization in patients with CHF.

Methods and results: Twenty-two patients with CHF were randomised to the non-selective β-blocker carvedilol or the selective β-blocker metoprolol (double-blind). Measurement of hemodynamics, arterial and coronary sinus free fatty acid (FFA) and lactate levels, and cardiac norepinephrine spillover (CANESP) were made before and after 4 months of therapy. In the carvedilol group (n=11), there was a significant reduction in myocardial FFA uptake (0.12±0.02 to 0.1±0.02 mmol/l, P<0.03). By contrast, in the metoprolol group (n=11) there was no change in myocardial FFA extraction. Carvedilol therapy tended to increase myocardial lactate extraction (0.24±0.05 to 0.35±0.08 mmol/l, P=0.08) while metoprolol therapy resulted in a trend in the opposite direction (0.18±0.03 to 0.11±0.04 mmol/l, P=0.09). The change in lactate extraction in the carvedilol group was significantly different from that in the metoprolol group (+0.11±0.06 vs. –0.09±0.04 mmol/l, P<0.01). Carvedilol treatment caused a significant reduction in CANESP while metoprolol had a neutral effect (–95±27 vs. 25±42 pmol/min, carvedilol vs. metoprolol P<0.03).

Conclusion: Carvedilol treatment caused a 20% reduction in myocardial free fatty acid extraction while metoprolol had a neutral effect. These differences are most probably related to the differential effects of these two agents on efferent cardiac sympathetic activity and may be relevant to the reported differential effects of these drugs on clinical outcomes.

Key Words: Heart failure • Receptors • Adrenergic • Beta • Nervous system • Sympathetic • Metabolism • Al-Hesayen • β-Blockers • Myocardial substrate utilization

Received February 14, 2004; Revised March 3, 2004; Accepted April 28, 2004


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
L. H. Opie and J. Knuuti
The adrenergic-Fatty Acid load in heart failure.
J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. Sharma, P. Dhillon, R. Wambolt, H. Parsons, R. Brownsey, M. F. Allard, and J. H. McNeill
Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1609 - H1620.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Ashrafian, M. P. Frenneaux, and L. H. Opie
Metabolic Mechanisms in Heart Failure
Circulation, July 24, 2007; 116(4): 434 - 448.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.